Low colonization rates with Multidrug-resistant Gram-negative bacteria in a German hospital-affiliated hemodialysis center

Ralph Wendt¹,², Olaf Nickel³, Almut Botsch¹, Margareta Lindner³, Angela Bethge³, Kathrin Marx⁴, Bernhard R. Ruf¹, Joachim Beige¹,²,⁵☯, Christoph Lübbert¹,⁶,⁷☯

¹ Department of Infectious Diseases/Tropical Medicine, Nephrology and Rheumatology, Hospital St. Georg, Leipzig, Germany, ² Kuratorium für Dialyse und Transplantation (KfH) Renal Unit, Hospital St. Georg, Leipzig, Germany, ³ Department of Laboratory Medicine and Microbiology, Hospital St. Georg, Leipzig, Germany, ⁴ Hospital Pharmacy, Hospital St. Georg, Leipzig, Germany, ⁵ Martin-Luther-University Halle/Wittenberg, Halle, Germany, ⁶ Division of Infectious Diseases and Tropical Medicine, Department of Oncology, Gastroenterology, Hepatology, Pneumology and Infectious Diseases, Leipzig University Hospital, Leipzig, Germany, ⁷ Interdisciplinary Center for Infectious Diseases, Leipzig University Hospital, Leipzig, Germany

☯ These authors contributed equally to this work.
* christoph.luebbert@medizin.uni-leipzig.de

Abstract

Background

Multidrug-resistant Gram-negative bacteria (MDRGN) are found with rising prevalence in non-hemodialysis risk populations as well as hemodialysis (HD) cohorts in Asia, Europe and North America. At the same time, colonization and consecutive infections with such pathogens may increase mortality and morbidity of affected individuals. We aimed to monitor intestinal MDRGN colonization in a yet not investigated German HD population.

Methods

We performed cross-sectional point-prevalence testing with 12 months follow-up and selected testing of relatives in an out-patient HD cohort of n = 77 patients by using microbiological cultures from fresh stool samples, combined with Matrix Assisted Laser Desorption Ionization—Time of Flight Mass Spectrometry (MALDI-TOF-MS) and antimicrobial susceptibility testing.

Results

We detected MDRGN in 8 out of 77 patients (10.4%) and 1 out of 22 relatives (4.5%), indicating only colonization and no infections. At follow-up, 2 patients showed phenotypic persistence of MDRGN colonization, and in 6 other patients de-novo MDRGN colonization could be demonstrated. Pathogens included Escherichia coli and Klebsiella pneumoniae (with extended-spectrum beta-lactamase [ESBL]-production as well as fluoroquinolone resistance), Stenotrophomonas maltophilia and Enterobacter cloacae.
Conclusions

In a single-center study, MDRGN colonization rates were below those found in non-HD high-risk populations and HD units in the US, respectively. Reasons for this could be high hygiene standards and a strict antibiotic stewardship policy with evidence of low consumption of fluoroquinolones and carbapenems in our HD unit and the affiliated hospital.

Introduction

Infections with antibiotic-resistant bacteria are a striking problem in patients with chronic diseases and compromised immune status. Among patients who require chronic hemodialysis (HD), Vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA) have been studied extensively [1–3] and showed important differences of Gram-positive bacteria distribution between European and other regions [4]. Other concerns have been raised in terms of spreading multidrug-resistant Gram-negative bacteria (MDRGN) among non-HD chronic-disease patient populations [1, 5, 6] since these pathogens are associated with up to five times higher mortality rates compared with susceptible Gram-negative bacteria regarding blood stream infections [7, 8]. In Western Europe, colonization and infection with MDRGN is emerging especially in healthcare-associated facilities such as nursing homes [9, 10] and intensive care units (ICUs) reaching colonization rates up to 53% [5]. In other parts of Europe and the world, MDRGN are even more widely distributed in the community setting [11–13] and among travelers [12, 14, 15].

Mortality among end-stage renal disease (ESRD) patients is multifold higher compared to the general population [16] with infections being the second most common reason to die [17]. Apparently, infection patterns are changing nowadays, with MRSA infections constituting a lower proportion compared to the rise of MDRGN infections [1] in both non-HD populations and presumably HD patients [6]. For instance, in the Boston area of the US in 2008 a MDRGN colonization rate of 27% was recorded in a large cohort of HD out-patients [18]. In a British HD center from 2011 to 2014, 84 patients experienced 95 Gram-negative infections [19]. Despite these trends, antimicrobial resistance among Gram-negative bacteria has not been previously investigated in chronic HD patients in Europe or Germany. Hence, data on the distribution of MDRGN in HD out-patients cohorts are scarce and the association between colonization and the risk for infections is not yet clear.

We therefore performed a cross-sectional point-prevalence study with sampling follow-up to determine the presence of MDRGN among out-patients who require chronic HD in our center in Leipzig, Germany.

Patients and methods

Study setting

Patients from a single HD unit were included in a prospective cohort study analyzing the period May 1, 2015 to June 30, 2017 after providing voluntary written informed consent. The out-patient unit services nephrological care for 167 patients and is affiliated with a large 1060-bed municipal hospital in Eastern Germany. Among the patients, 140 were able to consent and 77 agreed to participate (55%). Fifty-five of these 77 patients (71%) took part in a follow-up investigation 12 months later, and relatives (household members) of 22 patients gave consent as well and were tested following the same procedure. The reasons for non-
participation after 12 months were: 10 patients died, 9 patients rejected participation, and 3 patients were transplanted or had recovering kidney function. Trained nurses in the HD unit performed the collection of specimens for MDRGN testing by fecal sampling. All patients underwent 4-hour hemodialysis three times a week.

**Microbiological approach**

Specimens were primarily investigated by conventional microbiological cultures. Therefore, fresh stool samples were spread on non-selective Columbia blood agar, Gram-negative selective endo agar and chromogenic selective media (ChromID® ESBL agar, bioMérieux, Nürtingen, Germany, and Brilliance™ CRE medium, Oxoid, Wesel, Germany) (Fig 1A). Subsequently, commercially available antimicrobial susceptibility disks were applied to blood and endo agar plates (Becton Dickinson, Heidelberg, Germany) (Fig 1B). If adequate inhibitory zones were absent in the agar diffusion test, one representative colony of each phenotype was isolated from the area surrounding the antimicrobial disks for piperacillin, cefotaxime, ceftazidime, ciprofloxacin and ertapenem (Fig 1C). In parallel, colonies that grew on selective chromogenic media for extended spectrum beta-lactamases (ESBL) or carbapenemases were isolated accordingly (Fig 1D). Bacterial species from these isolates were identified by VITEK®-MS (bioMérieux, Nürtingen, Germany) using Matrix Assisted Laser Desorption Ionization—Time of Flight Mass Spectrometry (MALDI-TOF-MS) (Fig 1E).

![Fig 1](https://example.com/f1.png)

**Fig 1.** (A) Inoculation of stool samples on blood agar, endo agar, and chromogenic agar plates for ESBL and carbapenemase producers (ES and CA). (B) Application of antimicrobial susceptibility disks for piperacillin (P), cefotaxime (X), ceftazidime (T), ciprofloxacin (C) or ertapenem (E) to blood and endo agar plates. (C) After 24 hours of incubation at 36˚C one colony of each phenotype (grey spots) within the inhibition zones was isolated. (D) In parallel, colonies growing on selective chromogenic media were isolated. (E) The isolated strains were identified by MALDI-TOF-MS and susceptibility testing was performed by microdilution using the VITEK®2 system. Semi-automated MIC determination was performed using CLSI breakpoints. Suspected ESBL production within the isolated strains was confirmed by MIC strip ESBL testing.

[https://doi.org/10.1371/journal.pone.0240314.g001](https://doi.org/10.1371/journal.pone.0240314.g001)
Determination of minimum inhibitory concentrations (MIC) was carried out semi-automatically using the VITEK® 2 system and Advanced Expert System™ software (AES) (bioMérieux, Nürtingen, Germany) according to manufacturer’s instructions, employing Clinical and Laboratory Standards Institute (CLSI) breakpoints (Fig 1E) [20]. Strains producing ESBLs were confirmed by using MIC Test Strip ESBL technology (Cefotaxime / Cefotaxime + Clavulanic acid; Cefazidime / Cefazidime + Clavulanic acid; Liofilchem, Roseta, USA) (Fig 1E). Additional resistance against fluoroquinolones was confirmed by VITEK® 2-AST-N289/N248 cards (bioMérieux, Nürtingen, Germany). Classification of MDRGN was done according to the German national guideline (MDRGN are henceforth designated “Multi-Resistant Gram-Negatives”, MRGN, with the subtypes 3MRGN and 4MRGN, as summarized in Table 1) [21, 22].

All patients were informed about their test results by the supervising nephrologist.

Ethics approval

This work complies with ethical regulation for human studies and was conducted in accordance with the World Medical Association Declaration of Helsinki (1964) and its later amendments. Approval from the local ethics committee (Ethics Committee of the Saxonian Board of Physicians, Dresden, Germany) was obtained before the start of the study, specifically before data access and sample collection (EK-BR 52-15/1).

Statistics

Descriptive statistics of patient data with pseudonymized ID numbers were performed with standard procedures using MS Excel® (Microsoft, Redmond, Washington, USA).

Results

Out of a total of 77 patients, 2 tested initially positive for ESBL-producing *Escherichia (E.) coli* with fluoroquinolone co-resistance (3MRGN) (2.6%), 5 tested positive for *E. coli* with ESBL-production (6.5%), and 1 patient tested positive for *Stenotrophomonas maltophilia*. In 22 available samples from relatives, ESBL-producing *E. coli* with fluoroquinolone co-resistance (3MRGN) were observed in 1 person, but the resistance phenotype differed from that of the HD patient. No patient suffered from any illness related to MDRGN colonization during the observation period.

At follow-up after 12 months, 1 patient remained positive for ESBL-producing *E. coli* with fluoroquinolone co-resistance (3MRGN), 1 patient remained positive for *E. coli* with ESBL-production, and 6 other patients had evidence of de-novo colonization with MDRGN. One of these patients acquired an ESBL-producing *E. coli* strain with fluoroquinolone co-resistance

| Bacteria      | Categories¹ | Classification                      |
|---------------|-------------|-------------------------------------|
| Enterobacterales² | PIP, TAX or TAZ, CIP, ETP or IMI or MER or CARB | Resistance to three out of four categories |
|               | I, II, III, IV | 3MRGN                               |
|               |              |                                    | 4MRGN                               |

¹PIP = piperacillin, TAX = cefotaxime, TAZ = cefazidime, CIP = ciprofloxacin, ETP = ertapenem, IMI = imipenem, MER = meropenem, CARB = carbapenemase detected in the isolate irrespectively of the resistance phenotype, intermediate test results are considered as resistant for the classification.

²Enterobacterales includes a classification for the following species: *E. coli*, Klebsiella spp., Proteus spp., Citrobacter spp., Enterobacter spp., Serratia marcescens, Morganella spp., Providencia spp.

https://doi.org/10.1371/journal.pone.0240314.t001
between initial testing and follow-up, 3 patients acquired an *E. coli* strain with ESBL-production, and 2 patients acquired either multi-drug resistant *Klebsiella pneumoniae* or *Enterobacter cloacae* strains. Out of 5 patients with initial evidence of *E. coli* with ESBL-production, 4 showed spontaneous decolonization at follow-up.

The overall positivity rate of potentially pathogenic Gram-negative bacteria in all samples (initial, follow-up and relatives, n = 154) was 10.4%. Concerning tested patients, any colonization observed in either initial or follow-up sampling was noted in 14 out of 77 patients (18.1%). Among the pathogens, ESBL-producing *E. coli* constituted the most frequent finding, including 2 isolates with co-resistance to fluoroquinolones (3MRGN). No carbapenem-resistant isolates were detected. Colonization did not impact either morbidity or mortality within a follow-up period of 12 months.

**Discussion**

To our knowledge, this study is the first to investigate both follow-up sampling as well as MDRGN colonization rates of patients’ relatives in a HD setting. The observed colonization rates are far below those given in the literature in non-HD high risk populations such as nursing homes [6, 9] and HD units in the US [18], respectively. However, the applied methodology for MDRGN screening differs from other approaches cited in the literature [6, 9, 18]: Hogardt et al. exclusively used selective ESBL CHROMagar as primary screening media [9], and O’Fallon et al. and Pop-Vicas et al. relied on selective MacConkey agar containing low concentrations of fluoroquinolones and ceftazidime for screening [6, 18]. We believe that the combination of an agar diffusion test and two MDRGN selective media variants is probably more sensitive than a single selective media approach. Hence, it seems more likely that the observed low MRDGN colonization rates in our study are due to substantial differences in basic hygiene standards or (true) epidemiological reasons. Obviously, with a colonization rate of ESBL-producing *E. coli* with fluoroquinolone co-resistance (3MRGN) of approximately 3% and a complete absence of carbapenem-resistant bacteria, the background epidemiological pressure in our setting is not as high as it has been described in the literature.

Regarding antibiotic routine regimes both in out-patient dialysis as well as in the affiliated hospital, we sought to establish a robust and targeted conventional therapy for calculated initial and de-escalating therapy for Gram-negative infection with a wide variation and diversification of antibiotic usage, especially saving carbapenems [23, 24]. Compared to other large municipal hospitals in Germany we have a lower use of carbapenems and fluoroquinolones and a much higher stake of tetracyclines (primarily doxycycline), at least partially explaining the low 3MRGN colonization rate in our patients (Table 2) [25].

Future research should aim to target microbiological resistance profiles in HD populations under conditions of different antibiotic policies. In this respect, longitudinal investigations using serial testing for the appearance and disappearance of MDRGN colonization may help

### Table 2. Mean antibiotic application rates in recommended daily doses (RDD) per 100 hospital days in our inpatient nephrology ward including out- and inpatient dialysis unit during 2015, 2016 and 2017 in comparison to the average application rate of the 25% lowest using hospital sectors in Germany (right outer column) in the same time period [25].

|                | 2015 | 2016 | 2017 | Average consumption rate in the lowest-using 25% quartile of German hospitals (2015–2017) |
|----------------|------|------|------|-----------------------------------------------------------------------------------|
| RDD/100 hospital days |      |      |      |                                                                                   |
| Fluoroquinolones | 2.38 | 2.95 | 3.28 | 5.3                                                                               |
| Third generation cephalosporines | 2.48 | 3.89 | 3.98 | 2.9                                                                               |
| Carbapenems      | 0    | 0.06 | 0.24 | 1.6                                                                               |
| All antibiotics  | 4.86 | 6.91 | 7.5  | 9.8                                                                               |

https://doi.org/10.1371/journal.pone.0240314.t002
to understand environment–host interactions including selection pressure by antibiotics. A related issue affects the role of contacts between nursing personnel, in-patients and out-patients in HD units and the underlying compliance with hygiene standards, especially hand hygiene.

Limitations

Taking into account reports of cases testing MDRGN-negative for a period of time and converting again, possibly related to interrupted intestinal shedding of MDRGN, some authors suggest a series of at least 3 to 4 consecutive negative stool specimens, separated by sufficient time intervals (i.e., ≥1 week), before successful MDRGN decolonization is determined [26]. Moreover, we were unable to distinguish between persistence of MDRGN carriage and possible recolonization during HD stay as well as cross-transmission from relatives to HD patients and vice versa. Only the use of whole-genome sequencing might have allowed us to answer this question.

Conclusion

In conclusion, the present study contradicts the belief that HD units are MDRGN hotspots. MDRGN carriage was lower than observed in a similar US study and in non-HD, but high-risk populations, and was not associated with MDRGN infections.

Acknowledgments

We acknowledge the assistance of the nursing staff of the Kuratorium for Dialysis and Transplantation (KfH) Leipzig out-patient renal unit.

Author Contributions

Conceptualization: Ralph Wendt, Bernhard R. Ruf, Joachim Beige, Christoph Lübbert.
Data curation: Olaf Nickel, Almut Botsch, Margareta Lindner, Angela Bethge, Kathrin Marx.
Investigation: Olaf Nickel, Almut Botsch, Margareta Lindner, Angela Bethge, Joachim Beige.
Methodology: Joachim Beige, Christoph Lübbert.
Resources: Kathrin Marx.
Supervision: Bernhard R. Ruf, Joachim Beige, Christoph Lübbert.
Validation: Ralph Wendt, Christoph Lübbert.
Writing – original draft: Ralph Wendt, Joachim Beige, Christoph Lübbert.
Writing – review & editing: Ralph Wendt, Olaf Nickel, Almut Botsch, Margareta Lindner, Angela Bethge, Kathrin Marx, Bernhard R. Ruf, Joachim Beige, Christoph Lübbert.

References

1. Marston HD, Dixon DM, Knisely JM, Palmore TN, Fauci AS. Antimicrobial Resistance. JAMA. 2016; 316: 1193–1204. https://doi.org/10.1001/jama.2016.11764 PMID: 27654605
2. Benson L, Sprague B, Campos J, Singh N. Epidemiology of infection and colonization with vancomycin-resistant enterococci and frequency of cocolonization with methicillin-resistant Staphylococcus aureus in children. Infect Control Hosp Epidemiol. 2007; 28: 880–882. https://doi.org/10.1086/516454 PMID: 17564995
3. Lentino JR, Baddour LM, Wray M, Wong ES, Yu VL. Staphylococcus aureus and other bacteraemias in haemodialysis patients: antibiotic therapy and surgical removal of access site. Infection. 2000; 28: 355–360. https://doi.org/10.1007/s0010300507005 PMID: 11139154

4. Grünewald T, Lindner M, Weiß S, Ruf I, Treutler T, et al. Staphylococcus colonization, mortality and morbidity in haemodialysis patients: 10 years of observation. Int J Hyg Environ Health. 2013; 216: 751–754. https://doi.org/10.1016/j.ijheh.2013.02.005 PMID: 23517737

5. Maechler F, Pena Diaz LA, Schroder C, Jefferies C, Behnke M, Gastmeier P. Prevalence of carbapenem-resistant organisms and other Gram-negative MDRO in German ICUs: first results from the national nosocomial infection surveillance system (KISS). Infection. 2015; 43: 163–168. https://doi.org/10.1007/s15010-014-0701-6 PMID: 25395161

6. O’Fallon E, Schreiber R, Kandel R, D’Agata EMC. Multidrug-resistant gram-negative bacteria at a long-term care facility: assessment of residents, healthcare workers, and inanimate surfaces. Infect Control Hosp Epidemiol. 2009; 30: 1172–1179. https://doi.org/10.1086/648453 PMID: 19835474

7. D’Agata EMC. Addressing the Problem of Multidrug-Resistant Organisms in Dialysis. Clin J Am Soc Nephrol CJASN. 2018; 13: 666–668. https://doi.org/10.2215/CJN.13781217 PMID: 29567862

8. Vardakas KZ, Rafailidis PI, Konstantelias AA, Falagas ME. Predictors of mortality in patients with infections due to multi-drug-resistant Gram-negative bacteria: the study, the patient, the bug or the drug? J Infect. 2013; 66: 401–414. https://doi.org/10.1016/j.jinf.2012.10.028 PMID: 23142195

9. Hogardt M, Proba P, Mischler D, Cuny C, Kempf VA, Heudorf U. Current prevalence of multidrug-resistant organisms in long-term care facilities in the Rhine-Main region, Germany. 2013. Euro Surveill. 2015; 20(26): pii = 21171

10. Neumann N, Mischler D, Cuny C, Hogardt M, Kempf VAJ, Heudorf U. [Multidrug-resistant organisms (MDRO) in patients in outpatient care in the Rhine-Main region, Germany, in 2014: Prevalence and risk factors]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2016; 59: 292–300. https://doi.org/10.1007/s00103-015-2290-7 PMID: 26631014

11. Ny S, Kozlov R, Dempis U, Edquist P, Grondahl-Yi-Hannukela K, et al. Large variation in ESBL-producing Escherichia coli carriers in six European countries including Russia. Eur J Clin Microbiol Infect Dis. 2018; 37: 2347–2354. https://doi.org/10.1007/s10096-018-3382-8 PMID: 30338465

12. Meurs L, Lempp FS, Lippmann N, Trawinski H, Rodloff AC, et al. Intestinal colonization with extended-spectrum beta-lactamase-producing Enterobacteriales (ESBL-PE) during long-distance travel: A cohort study in a German travel clinic (2016–2017). Travel Med Infect Dis. 2019; 101521. https://doi.org/10.1016/j.tmaid.2019.101521 PMID: 31770602

13. Doi Y, Iovleva A, Bonomo RA. The ecology of extended-spectrum beta-lactamases (ESBLs) in the developed world. J Travel Med. 2017; 24: S44–S51. https://doi.org/10.1093/jtm/taw102 PMID: 28521000

14. Wendt S, Böhm P, Daniel J, Lippmann N, Lübbert M. How are travelers colonized with antimicrobial-resistant bacteria? J Travel Med. 2019. https://doi.org/10.1093/mta/jaz068 PMID: 31502644

15. Lübbert C, Straube L, Stein C, Makarewicz O, Schubert S, et al. Colonization with extended-spectrum beta-lactamase-producing and carbapenemase-producing Enterobacteriaceae in international travelers returning to Germany. Int J Med Microbiol. 2015; 305: 148–156. https://doi.org/10.1016/j.ijmm.2014.12.001 PMID: 25547265

16. Foley RN, Parfrey PS. Cardiovascular disease and mortality in ESRD. J Nephrol CJASN. 1998; 11: 239–245. PMID: 9831236

17. Lacson EJ Jr., Wang W, Hakim RM, Teng M, Lazarus JM. Associates of mortality and hospitalization in hemodialysis: potentially actionable laboratory variables and vascular access. Am J Kidney Dis. 2009; 53: 79–90. https://doi.org/10.1053/ajkd.2008.07.031 PMID: 18930570

18. Pop-Vicas A, Strom J, Stanley K, D’Agata EMC. Multidrug-resistant gram-negative bacteria among patients who require chronic hemodialysis. Clin J Am Soc Nephrol. 2008; 3: 752–758. https://doi.org/10.2215/CJN.04651107 PMID: 18322047

19. Murray EC, Marek A, Thomson PC, Coia JE. Gram-negative bacteraemia in haemodialysis. Nephrol Dial Transplant. 2015; 30(7): 1202–8. https://doi.org/10.1093/ndt/gfv205 PMID: 25958400

20. Clinical and Laboratory Standards Institute (CLSI). Microbiology Standards Subcommittees & Resources. Online available from: https://clsi.org/standards/

21. KRINKO. Antibiotikaresistenz: Definition von Multiresistenz bei gramnegativen Erregern. Epidemiol Bull. 2011; 36: 337–339.

22. Surveillance nosokomialer Infectionen sowie die Erfassung von Krankheitsereignissen mit speziellen Resistzen und Multiresistenzen. Bundesgesundheitsblatt—Gesundheitsforschung—Gesundheitsschutz. 2013; 56: 580–583. https://doi.org/10.1007/s00103-013-1705-6 PMID: 23529603
23. Warren DK, Hill HA, Merz LR, Kollef MH, Hayden MK, et al. Cycling empirical antimicrobial agents to prevent emergence of antimicrobial-resistant Gram-negative bacteria among intensive care unit patients. Crit Care Med. 2004; 32: 2450–2456. https://doi.org/10.1097/01.ccm.0000147685.79487.28 PMID: 15599150

24. Kommission für Krankenhaushygiene und Infektionsprävention (KRINKO). Hygienemaßnahmen bei Infektionen oder Besiedlung mit multiresistenten gramnegativen Stäbchen. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2012; 55: 1311–1354. https://doi.org/10.1007/s00103-012-1549-5 PMID: 23011096

25. Kern W, Fellhauer M, de With K. Krankenhausvergleichsreport 2016/2017, ADKA-if-DGi-Projekt. Online available from: http://www.antiinfektiva-surveillance.de/files/kvr_2016_2017_published_270418_geschwaerzt.pdf.

26. Lübbert C, Lippmann N, Busch T, Kaisers UX, Ducomble T, et al. Long-term carriage of Klebsiella pneumoniae carbapenemase-2-producing K pneumoniae after a large single-center outbreak in Germany. Am J Infect Control. 2014; 42: 376–80. https://doi.org/10.1016/j.ajic.2013.12.001 PMID: 24679563